Impact of CYP2D6 genotype and co-medication with paroxetine and clarithromycin on clomiphene metabolism in vivo

被引：0
|
作者：
Muerdter, T. [1 ,2 ]
Lehr, T. [3 ]
Igel, S. [1 ,2 ]
Kroener, P. [1 ,2 ]
Ganchev, B. [1 ,2 ]
Schaeffeler, E. [1 ,2 ]
Boehmer, G. [4 ]
Sonnenberg, M. [1 ,2 ]
Brauch, H. [1 ,2 ]
Kerb, R. [1 ,2 ]
Schwab, M. [1 ,2 ,4 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[2] Univ Tubingen, Stuttgart, Germany
[3] Univ Saarland, Klin Pharm, Saarbrucken, Germany
[4] Univ Klinikum Tubingen, Klin Pharmakol Abt, Tubingen, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2016年 / 389卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
021
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [31] IMPACT OF CYP2D6 GENOTYPE ON POSTOPERATIVE INTRAVENOUS OXYCODONE ANALGESIA
    Zwisler, S. T.
    Enggaard, T. P.
    Mikkelsen, S.
    Brosen, K.
    Sindrup, S. H.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 26 - 26
  • [32] CYP2D6 Genotype and Adjuvant Tamoxifen
    Berry, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 138 - 140
  • [33] CYP2D6 genotype and tardive dyskinesia
    Sajjad, SHA
    BRITISH JOURNAL OF PSYCHIATRY, 1997, 170 : 580 - 580
  • [34] CYP2D6 genotype and tamoxifen response
    Rae, JM
    Goetz, MP
    Hayes, DF
    Ingle, JN
    Li, L
    Storniolo, AM
    Stearns, V
    Flockhart, DA
    BREAST CANCER RESEARCH, 2005, 7 (05)
  • [35] CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6
    MCLEOD, HL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 463 - 463
  • [36] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [37] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [38] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [39] Population pharmacokinetic evaluation of the relevance of CYP2D6 genotype on risperidone metabolism
    Locatelli, I
    Kastelic, M.
    Koprivsek, J.
    PHARMACOGENOMICS, 2011, 12 (03) : 312 - 313
  • [40] Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo
    Ozdemir, V
    Naranjo, CA
    Shulman, RW
    Herrmann, N
    Sellers, EM
    Reed, K
    Kalow, W
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (03) : 198 - 207
12345